New US risk class for human dura mater
This article was originally published in Clinica
Executive Summary
The US FDA has announced that human dura mater has been categorised as a class II product subject to special controls. As a result, companies wishing to sell the human material to repair defects in human dura mater will need to comply with a new guidance when they submit their 510(k)s. The guidance recommends clinical and histopathological methods, such as next of kin interviews and full brain autopsy intended to identify and defer potential donors who have vCJD/CJD.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.